Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Date:8/12/2008

Medarex to Receive Milestone Payment from MedImmune

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.

The Phase 2A clinical trial is designed to evaluate the safety and tolerability of multiple subcutaneous dose schedules of MEDI-545 or placebo in adult patients with moderate to severe active lupus. The study will also assess the effects of MEDI-545 on disease activity in lupus patients. This randomized, double-blind, placebo-controlled trial is expected to enroll 80 patients and will be conducted at 20 sites in the United States.

MedImmune is also conducting a Phase 1 clinical trial for MEDI-545 in idiopathic inflammatory myositis, an immunological disease that involves chronic muscle inflammation, pain and weakness.

"Data from an earlier reported placebo-controlled Phase 1 study suggested therapeutic activity with single doses in patients with lupus and demonstrated an acceptable safety profile," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are very excited about the role of the interferon alpha inflammatory pathway and look forward to exploring its potential in treating patients with lupus and other autoimmune diseases."

About MEDI-545

MEDI-545 (previously known as MDX-1103) is a fully human monoclonal antibody targeting
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 Reportlinker.com announces that ... in its catalogue: Bioseparation ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... types: chromatography, membranes/filters and centrifuges. The demand ... fueling growth of the global bioseparations market. ...
(Date:8/18/2014)... -- Reportlinker.com announces that a new market research report ... Russia Sinuscopes Market Outlook to 2020 ... to 2020 Summary GlobalData,s ... key market data on the Russia Sinuscopes market. The ... (in units) and average prices (in US dollars) within ...
(Date:8/18/2014)... , Aug. 18, 2014  Pharmacyclics, Inc. (NASDAQ: ... Shawn Cline Tomasello as its Chief Commercial ... and former President of the Americas, Hematology and Oncology, ... billion in revenue. Prior to joining Celgene, Ms. Cline ... ® at Genentech, where she was responsible for ...
Breaking Medicine Technology:Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4Pharmacyclics Appoints Chief Commercial Officer 2Pharmacyclics Appoints Chief Commercial Officer 3Pharmacyclics Appoints Chief Commercial Officer 4
... to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell, ... ... Percent., Accurate Diagnosis is Important for Guiding ... Rates of Severe or Fatal Hemorrhage in Patients With Squamous NSCLC ...
... California, April 3 ,Results of an independent ... the first clinically proven non-invasive solution,for fat ... focused,ultrasound will be presented at the American ... on April 4, 2008 in Kissimmee, Florida. ...
Cached Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting 2UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting 3
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
(Date:8/20/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... System in Hermiston, Ore. The top executive search ... has recently placed more than 900 healthcare executives into ... a progressive, not-for-profit healthcare organization serving a population of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Oxnard ... founder of the Anacapa Dental Art Institute, is presenting ... Dr. Jivraj will be speaking on All-on-4 dental ... Aspects of Graft Less Solutions” at 12:40 p.m. Sept. ... in Vancouver, British Columbia, Canada. , “The All-on-4 procedure ...
(Date:8/20/2014)... Washington, DC (PRWEB) August 20, 2014 ... Got Heart, Give Hope® Celebration to be hosted in ... Army and Navy Club. This signature event honors the ... the families of the fallen. Proceeds from the Got ... Warriors®, a national nonprofit dedicated to restoring a sense ...
Breaking Medicine News(10 mins):Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 2Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2
... MENLO PARK, Calif., Oct. 23 SRI International, ... today that Dr. Elizabeth Shriberg, a senior researcher ... has been named a Fellow of the International ... at Interspeech 2009 in Brighton, England, recognizes significant ...
... SILVER SPRING, Md., Oct. 23 The U.S. Food ... a request from the U.S. Centers for Disease Control ... (EUA) for the investigational antiviral drug peramivir intravenous (IV) ... suspected 2009 H1N1 influenza infection who are admitted to ...
... International Dairy Foods Association applauded Agriculture Secretary Tom Vilsack ... offering more low fat milk and dairy products in ... improve the quality of school meals, one of the ... outlined the Obama Administration,s agenda for Child Nutrition Act ...
... Singer/Songwriter Patti Austin Headline Annual Andrus Awards Gala ... leadership in communication , LAS VEGAS, Oct. 24 ... to acclaimed television pioneer Norman Lear at a celebration ... and expo. Lear, creator of shows including " All in the ...
... Surgery 2009 News Briefs are designed to keep you ... at the annual meeting of the American Society of ... briefs are embargoed until the date/time they are presented. ... for media registration, or to arrange interviews with presenters, ...
... that injection sting is excessive disputed in U.S. study , ... that injections of the human papillomavirus (HPV) vaccine are especially ... more than any other shots. , Public health officials worried ... getting the vaccine, which protects against a virus that can ...
Cached Medicine News:Health News:SRI International Researcher Receives International Speech Communication Association (ISCA) Fellow Award 2Health News:SRI International Researcher Receives International Speech Communication Association (ISCA) Fellow Award 3Health News:FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings 2Health News:IDFA Supports Obama Administration's Commitment to Encourage Schools to Provide More Low Fat Milk and Dairy Products in Schools 2Health News:Legendary TV Producer Norman Lear Receives AARP's Highest Honor 2Health News:Legendary TV Producer Norman Lear Receives AARP's Highest Honor 3Health News:Plastic Surgery 2009 news briefs 2Health News:Plastic Surgery 2009 news briefs 3Health News:Plastic Surgery 2009 news briefs 4Health News:Plastic Surgery 2009 news briefs 5Health News:Plastic Surgery 2009 news briefs 6Health News:HPV Vaccine No More Painful Than Other Shots 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: